CKD-512

· Chong Kun Dang Pharmaceutical

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CKD-512, covering 2026-02-02 to 2026-02-02. Get the full timeline:

Most recent: Clinical Trial Update: Phase Ia/Ib Study of CKD-512 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Solid Tumors [Phase 1]

See pricing